Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Hepatic encephalopathy Stories

2014-04-11 00:21:56

LONDON, April 11, 2014 /PRNewswire/ -- - Hepatic encephalopathy (HE) is associated with a significant increase in mortality (58.1% vs. 32.4%), as well as longer hospital stays (8 days vs. 6.8 days) and more primary care visits (18.2 vs. 8.7 contacts per patient year) compared to similar liver patients without HE[i],[ii] - XIFAXAN(R) 550 (rifaximin-alpha) is a cost-effective treatment option for the...

2013-09-09 12:27:29

LONDON, September 9, 2013 /PRNewswire/ -- Norgine today announced that the Scottish Medicines Consortium (SMC) has accepted the use, within NHS Scotland, of TARGAXAN(R) 550 (rifaximin-alpha),[i] a treatment licensed for the reduction in recurrence of episodes of overt hepatic encephalopathy in patients of 18 years of age and over.[ii] (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) This is the second acceptance for use made by a health technology...

2013-05-24 08:22:25

LONDON, May 24, 2013 /PRNewswire/ -- Norgine today announced that the Australian assessment body the Pharmaceutical Benefits Advisory Committee (PBAC) has recommended the use of XIFAXAN 550 mg in the prevention of the recurrence of hepatic encephalopathy (HE) where other treatments have failed or are contraindicated; a potentially life-threatening neuropsychiatric condition associated with liver disease. XIFAXAN 550 mg is the only treatment that has demonstrated a...

2013-04-25 19:49:37

Probiotics could emerge as a treatment plan to manage hepatic encephalopathy (HE) therapy after a new study announced at the International Liver Congress 2013 found they significantly reduced development of the notoriously difficult-to-treat disease. The study analysed the efficacy of probiotics in preventing the development of HE in 160 cirrhotic patients over a period of approximately nine months and found significant improvements in reducing patients' arterial ammonia levels after three...

2012-11-11 08:20:20

BOSTON, Nov. 11, 2012 /PRNewswire/ -- Minimal hepatic encephalopathy (MHE), which is often found in patients with cirrhosis, is difficult to diagnose. This is an important issue because MHE is associated with poor quality of life, progression to severe disease, unemployment, and traffic accidents and can be treated if it is diagnosed. A smartphone app for Stroop task, which is used to evaluate psychomotor speed and cognitive flexibility, could be used to screen for MHE....

2012-11-08 08:34:56

SAN DIEGO, Nov. 8, 2012 /PRNewswire/ -- Ocera Therapeutics, Inc. announced that the first patient has enrolled in a Phase 2a study to evaluate the safety and tolerability of OCR-002 (ornithine phenylacetate) in the treatment of patients with acute liver injury (ALI) as well as those that have progressed to acute liver failure (ALF) following acetaminophen overdose. OCR-002 is an investigational drug designed to directly reduce circulating blood levels of ammonia which, at high levels, is...

2012-05-29 02:26:48

BARCELONA, Spain and SAN DIEGO, May 29, 2012 /PRNewswire/ --- Hospital Universitari Vall d'Hebron Research Institute in Barcelona and Ocera Therapeutics, Inc. announced today preliminary data from an open label phase 2 study evaluating the overall effectiveness and safety of OCR-002 (ornithine phenylacetate) for the treatment of cirrhosis of the liver and upper GI bleeding. An interim analysis of the first cohort of patients demonstrated that OCR-002 is well tolerated and provided a rapid and...

2012-03-28 00:38:31

Inhibitory control test and lactulose saves more than $3 million over 5 years A late stage liver condition, known as minimal hepatic encephalopathy (MHE), is associated with impaired driving skills and greater risk of motor vehicle accidents. Cost analysis of management strategies for detection and treatment of MHE are published in the April issue of Hepatology, a journal of the American Association for the Study of Liver Diseases. Findings report that MHE diagnosis using the inhibitory...

2011-07-21 14:08:57

Measures to reduce BMI may improve outcome for cirrhosis patients Researchers from the United States and Europe involved in an NIH-funded multicenter study have determined that increased body mass index (BMI) is an independent predictor of clinical decompensation in patients with compensated cirrhosis, independent of portal pressure and liver function. The findings suggest obesity accelerates cirrhosis progression and measures to reduce BMI could improve the prognosis for patients with...

2011-03-18 15:11:01

In liver-disease patients, cognitive impairment may not be fully reversible There are potential legal ramifications for physicians of patients who drive with cognitive impairment, according to a study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association (AGA) Institute. Between 20 and 60 percent of patients with cirrhosis (a condition in which the liver is permanently scarred or injured by chronic conditions and diseases) are...